+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Alzheimer's Disease - Pipeline Review, H2 2020

  • ID: 5146901
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 1785 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 1st Bio Therapeutics Inc
  • ADRx Inc
  • Alzamend Neuro Inc
  • Antoxerene Inc
  • Arvinas Inc
  • Autifony Therapeutics Ltd
  • MORE
Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease - Pipeline Review, H2 2020, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews the key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 21, 61, 77, 1, 4, 345, 134 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 2, 100 and 47 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 1st Bio Therapeutics Inc
  • ADRx Inc
  • Alzamend Neuro Inc
  • Antoxerene Inc
  • Arvinas Inc
  • Autifony Therapeutics Ltd
  • MORE
Introduction
  • Alzheimer's Disease - Overview
  • Alzheimer's Disease - Therapeutics Development
Alzheimer's Disease - Therapeutics Assessment

Alzheimer's Disease - Companies Involved in Therapeutics Development

Alzheimer's Disease - Drug Profiles

Alzheimer's Disease - Dormant Projects
  • Alzheimer's Disease - Discontinued Products
  • Alzheimer's Disease - Product Development Milestones
Appendix

List of Tables
  • Number of Products under Development for Alzheimer's Disease, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020 (Contd..1), H2 2020
  • Alzheimer's Disease - Pipeline by 1st Bio Therapeutics Inc, H2 2020
  • Alzheimer's Disease - Pipeline by 2A Pharma AB, H2 2020
  • Alzheimer's Disease - Pipeline by 4P-Pharma SAS, H2 2020
  • Alzheimer's Disease - Pipeline by AB Science SA, H2 2020
  • Alzheimer's Disease - Pipeline by Abaxy Sprl, H2 2020
List of Figures
  • Number of Products under Development for Alzheimer's Disease, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
Note: Product cover images may vary from those shown
3 of 3
  • 1st Bio Therapeutics Inc
  • 2A Pharma AB
  • 4P-Pharma SAS
  • AB Science SA
  • Abaxy Sprl
  • AbbVie Inc
  • AC Immune SA
  • Acadia Pharmaceuticals Inc
  • Accuitis Pharmaceuticals Inc
  • Acelerox LLC
  • Acelot Inc
  • Actinogen Medical Ltd
  • Acumen Pharmaceuticals Inc
  • Addex Therapeutics Ltd
  • Adocia SAS
  • ADRx Inc
  • Aerobyx LLC
  • AfaSci Inc
  • Affichem SA
  • Aibios Co Ltd
  • Alector Inc
  • Alfasigma SpA
  • Alkahest Inc
  • Alkermes Plc
  • AlphaCognition Inc
  • Alsonex Pty Ltd
  • ALSP Inc
  • Alzamend Neuro Inc
  • AlzeCure Pharma AB
  • Alzheon Inc
  • Alzhyme Pty Ltd
  • Alzinova AB
  • AlzProtect SAS
  • Alzyn LLC
  • Amyloid Solution Inc
  • Amylon LLC
  • Amylyx Pharmaceutical Corp
  • Anavex Life Sciences Corp
  • Ankar Pharma SL
  • Annovis Bio Inc
  • Antoxerene Inc
  • Anven AlzDx Inc
  • Aphios Corp
  • Apodemus AB
  • Apollo Therapeutics LLC
  • Applied Research using OMIC Sciences SL
  • Aprinoia Therapeutics Inc
  • AptaBio Therapeutics Inc
  • Araclon Biotech SL
  • Archer Pharmaceuticals Inc
  • AriBio
  • ArmaGen Inc
  • Armgo Pharma Inc
  • Artery Therapeutics Inc
  • Arvinas Inc
  • Asceneuron SA
  • Asdera LLC
  • AskAt Inc
  • Asklepios BioPharmaceutical Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Astrocyte Pharmaceuticals Inc
  • AstronauTx Ltd
  • Athira Pharma Inc
  • ATP Biopharm
  • Augustus BioTarget Inc
  • Auransa Inc
  • Aurin Biotech Inc
  • Auritec Pharmaceuticals Inc
  • Autifony Therapeutics Ltd
  • Autophagy Neurotherapeutics Inc
  • Avanti Biosciences Inc
  • Avidin Biotechnology Ltd
  • Avineuro Pharmaceuticals Inc
  • Axon Neuroscience SE
  • Axxam SpA
  • AZTherapies Inc
  • BCWorld Pharm Co Ltd
  • Benuvia Therapeutics Inc
  • Berg LLC
  • BeyondBio Inc
  • Bio-Pharm Solutions Co Ltd
  • BioArctic AB
  • Biogen Inc
Note: Product cover images may vary from those shown
Adroll
adroll